Proposed UK medical-device licensing powers: a glove buyer’s guide

MHRA described three groups of amendments: information-sharing powers, measures intended to make medicines and medical-device legislation easier to update, and enabling powers for the future development of a medical-device licensing regime. The licensing proposal would amend the Medicines and Medical Devices Act 2021.

The published amendment text would allow future medical-device regulations to address product licences for supply or advertising and personal licences for activities such as manufacturing, importing or wholesale supply. It also provides possible powers concerning conditions, duration, renewal, variation, suspension, revocation, transfer, exemptions, registers, offences and fees. These are enabling provisions, not a finished operating scheme.

MHRA explicitly says the proposals make no immediate change to medicines or medical-device regulation. A buyer should not request a new licence number, remove an approved product or rewrite a tender as though a future regime were already in force.

The current Great Britain framework remains based on the UK Medical Devices Regulations 2002. Medical devices placed on the Great Britain market must follow the applicable conformity, marking and registration rules. All medical devices need MHRA registration before placement on the Great Britain market, and a manufacturer based outside the UK must appoint a UK responsible person for that market.

• Keep using the current intended-purpose and classification assessment.
• Keep checking the exact declaration, certificate where applicable, marking and registration route.
• Do not replace current evidence with a reference to the proposal.
• Do not predict licence numbers, costs, dates or product outcomes.

UKCA remains an available domestic marking route for medical devices in Great Britain. MHRA says it will remain in place while any future licensing model is developed. The official guidance also sets out continued acceptance of eligible CE-marked devices in Great Britain, with end dates depending on the legislation and device route involved.

For a medical glove, record the actual route relied on by the exact product rather than copying the latest possible transition date into every file. Check that the declaration remains valid, any certificate applies to the product and status concerned, and the registration and economic-operator details align with the label and supply chain.

MHRA guidance states that EU Medical Device Regulation requirements apply in Northern Ireland and that CE marking is required there, with UKNI also required when a UK notified body carries out mandatory third-party conformity assessment. MHRA's proposal note says Northern Ireland continues to apply the EU medical-device framework under the Windsor Framework.

Do not use a Great Britain-only UKCA route as evidence for Northern Ireland. A programme supplying both destinations should identify which units, declarations, marks, economic operators and registrations support each route, including any UKNI implications for the exact product.

The most useful response is to make the current product record easier to review when official details emerge. Assign one owner to monitor the Health Bill, MHRA medical-device guidance and any future consultation. Record the date and source of each status check so an old proposal is not mistaken for a current requirement.

Avoid asking suppliers to certify compliance with rules that do not exist. Instead, ask who would coordinate future regulatory change, how the legal manufacturer and other operators receive updates, and how artwork, declarations, registration and stock would be controlled if a future rule affected the product.

Keep the following fields current for every exact glove so a later impact assessment can begin from reliable information.

• Exact product name, reference, formulation, sizes and sterile status where relevant.
• Stated intended purpose and current medical-device classification.
• Legal manufacturer and manufacturing-site relationship.
• UK responsible person where required, importer and distributor roles.
• MHRA registration route and current product identifiers.
• UKCA, CE or CE and UKNI route actually relied on for each destination.
• Declaration of conformity, applicable certificate and supporting technical evidence.
• Label, instructions, pack artwork, lot traceability and shelf-life controls.
• Destination markets and the person responsible for regulatory change control.

Use proportionate questions that clarify ownership without implying a regulatory outcome. The final detail may change through Parliament, consultation and later regulations.

• Who monitors UK Parliament and MHRA updates for this exact product?
• Which current route places the glove on the Great Britain market?
• Is Northern Ireland in scope, and which separate evidence supports it?
• Can the declaration, registration information and label be matched to one product reference?
• How will a future regulatory change trigger artwork, document, stock and customer review?
• Which assumptions in the current contract or tender would need legal or regulatory confirmation?

Status checked on 9 September 2026. Review this guidance by 9 October 2026, or earlier if UK Parliament records a decision on the amendment, the Bill advances to a relevant stage, or MHRA publishes a consultation, impact assessment or detailed licensing proposal.

Until then, the practical task is current compliance: verify the exact glove's intended purpose, market route, registration, conformity evidence, labelling and supply-chain roles. The proposed powers should be monitored, but they should not be presented as an enacted licensing system.